Results 301 to 310 of about 457,600 (353)

Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection. [PDF]

Front Oncol
Li J, Sun Y, Liu Z, Huang J, Wu J, Huang Y, Gao Y, Chen B, He Q.   +8 more
europepmc   +1 more source

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges. [PDF]

Ann Hematol
Wang Y, Zhang Y, Liu J, Jiang Y, Li J, Shi W.   +5 more
europepmc   +1 more source

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis. [PDF]

Oncologist
Dias E Silva D, Pernomian LS, Fernandes M, Lenzi MC, Gazzoni G, Fonseca AC, Silveira L, Beal JR, Junior PLSU, Moura F, Garcia RJ, Pestana RC.   +11 more
europepmc   +1 more source

APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1-ALK Positive Anaplastic Large Cell Lymphoma. [PDF]

Cancer Sci
Liu Z, Jing X, Li D, Bao L, Liu Y, Hang R, Kuang X, Jiang Z, Dai X, Tong X, Tell G, Li M.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +4 more sources

Inhibitors of tyrosine kinase

Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire   +2 more sources

Inhibitors of protein tyrosine kinases

Current Opinion in Biotechnology, 1995
The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire   +2 more sources

FLT3 Tyrosine Kinase Inhibitors

International Journal of Hematology, 2005
The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome.
Mark, Levis, Donald, Small
openaire   +2 more sources

Tyrosine Kinase Inhibitors and Cancer Therapy

Clinical Biochemistry, 2004
Cancer is the second leading cause of death in the western world. Despite advances in diagnosis and treatment, overall survival of patients remains poor. Scientific advances in recent years have enhanced our understanding of the biology of cancer. Human protein tyrosine kinases (PTKs) play a central role in human carcinogenesis and have emerged as the ...
Srinivasan, Madhusudan, Trivadi S, Ganesan   +1 more
openaire   +3 more sources